论文部分内容阅读
目的 研究支气管动脉灌注化疗联合直线加速器放射治疗Ⅲa期非小细胞肺癌 (NSCLC)的可行性及临床价值。方法 76例NSCLC患者随机分成A、B 2组 ,A组先行 2次支气管动脉灌注化疗 (BAI) ,第 2次BAI 1～ 2周后再行直线加速器放射治疗 (RT) ;B组单纯行 2次BAI (对照组 )。结果 临床疗效 ,A组 (BAI +RT)和B组 (BAI)分别为 89.47%和 60 .5 3% (Ρ <0 .0 1) ;1、3年生存率 ,A、B组分别为 81.5 8%、5 0 .0 0 %和 60 .5 3%、2 1.0 5 % ( 0 .0 1<Ρ <0 .0 5 )。结论 支气管动脉灌注化疗联合直线加速器放射治疗Ⅲa期非小细胞肺癌的临床疗效和患者 1、3年生存率均显著提高
Objective To study the feasibility and clinical value of bronchial artery infusion chemotherapy combined with linear accelerator radiotherapy for stage Ⅲ a non-small cell lung cancer (NSCLC). Methods A total of 76 patients with NSCLC were randomly divided into two groups: group A and group B, group A received bronchial artery infusion chemotherapy (BAI) 2 times first, and group 1 received linear accelerator radiation therapy (RT) after group 1 to 2 weeks. Secondary BAI (control group). Results The clinical curative effect was 89.47% in group A and 60.53% in group B (P <0.01). The 1-year and 3-year survival rates of group A and group B were 81.5 8%, 50.0% and 60.5%, 2 1.05% (0 .0 1 <Ρ <0. 05). Conclusions The clinical efficacy of bronchial arterial infusion chemotherapy combined with linear accelerator radiotherapy for stage Ⅲ a non-small cell lung cancer and the 1-year and 3-year survival rates of patients were significantly increased